Glenmark Pharmaceuticals gets final approval for Clindamycin Phosphate Gel from USFDA

11 Feb 2021 Evaluate

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1%, the generic version of Cleocin T1 Gel, 1%, of Pharmacia & Upjohn. Sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.

Glenmark’s current portfolio consists of 169 products authorized for distribution in the U.S. marketplace and 42 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. 

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1981.50 -19.10 (-0.95%)
19-Jan-2026 10:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1661.85
Dr. Reddys Lab 1170.20
Cipla 1376.35
Zydus Lifesciences 864.75
Lupin 2167.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×